Search

Displaying results 1811 - 1820 of 7687 in total
  1. Drug

    Iohexol

    go.drugbank.com/drugs/DB01362
    ApprovedInvestigational

    Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.

  2. Drug

    Hydroxyethyl Starch

    go.drugbank.com/drugs/DB09106
    ApprovedInvestigational

    HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.

  3. Drug

    Clofazimine

    go.drugbank.com/drugs/DB00845
    ApprovedInvestigationalWithdrawn

    [A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis

  4. Drug

    CoviGlobulin

    go.drugbank.com/drugs/DB15747
    Experimental

    The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones.

  5. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342] … This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction.

  6. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malign...

    Synonyms: 2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine
  7. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets

  8. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.

  9. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011. … Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial.

  10. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.

    Synonyms: D-glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1s)-